Lilly's EloraTZP Delivers Weight Loss Results In Phase 2b Trial
(RTTNews) - Eli Lilly and Company (LLY) said on Wednesday that its investigational EloraTZP combination of eloralintide and tirzepatide delivered substantial weight loss and reductions in blood sugar levels in a Phase 2b trial involving 367 adults with obesity or overweight and t
We haven't written up this one. Nasdaq Markets has the full story — the link below goes straight to it.